BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

OncoGenex Technologies Inc. 

400 - 1001 West Broadway

Vancouver  B.C.  V6H 4B1  Canada
Phone: 604-736-3678 Fax: 604-736-3687


SEARCH JOBS


Industry
Biotechnology






 Company News
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 8/22/2008 6:23:42 AM    More...
Sonus Pharmaceuticals, Inc. (SNUS) and OncoGenex Technologies Inc. Complete Business Combination 8/21/2008 8:10:20 AM    More...
Sonus Pharmaceuticals, Inc. (SNUS)'s Stockholders Approve Business Combination With OncoGenex Technologies Inc. 8/20/2008 6:17:24 AM    More...
OncoGenex Technologies Inc. Receives Completed Special Protocol Assessment for Primary Registration Study of Lead Drug Candidate OGX-011 7/14/2008 6:17:56 AM    More...
OncoGenex Technologies Inc. Increases Economic Interest in Lead Cancer Drug OGX-011 7/3/2008 6:33:44 AM    More...
Isis Pharmaceuticals, Inc. (ISIS)' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology 6/2/2008 11:22:52 AM    More...
OncoGenex Technologies Inc. Reports That Low Serum Clusterin Levels Were Predictive Of Survival In Preliminary Analyses Of Phase 2 Study Of Lead Drug Candidate OGX-011 Encouraging Survival Duration Continues With OGX-011 Plus Second-Line Chemotherapy For The Treatment Of Prostate Cancer; Data Presented At The 2008 Annual Meeting Of The American Society of Clinical Oncology 6/2/2008 9:43:37 AM    More...
Sonus Pharmaceuticals, Inc. (SNUS) and OncoGenex Technologies Inc. to Merge 5/28/2008 6:35:01 AM    More...
OncoGenex Technologies Inc. Reports Updated Survival Data on OGX-011 in a Second-line Chemotherapy Trial for Patients with Prostate Cancer Updated Data to be Presented at the 2008 Annual Meeting of the American Society of Clinical Oncology 5/16/2008 12:03:49 PM    More...
OncoGenex Technologies Inc. Reports Lead Drug Candidate OGX-011 Achieved Primary Endpoint in Phase 2 Trial 2/15/2008 6:20:03 AM    More...
1234

//-->